Newsletter and Current Position Update – 6/01/12

RIGHT NOW! IN THE CURRENT NEWSLETTER!

Six analysts rate this biotech a STRONG BUY or a BUY as it develops drugs for such diseases as lupus and has alliances with some big name pharmaceuticals; trading at around $2.00.

And six analysts also rate this biotech a STRONG BUY or a BUY as it develops products for treating central nervous system disorders; trading at under $3.00.